Identification of novel p38α MAP kinase inhibitors using fragment-based lead generation

Journal of Medicinal Chemistry

Volumn 48, Issue 2, 2005, Pages 414-426

  Gill, Adrian L ^a,b   Frederickson, Martyn ^a,b   Cleasby, Anne ^a,c   Woodhead, Steven J ^a,b   Carr, Maria G ^a,b   Woodhead, Andrew J ^a,b   Walker, Margaret T ^a,b   Congreve, Miles S ^a,b   Devine, Lindsay A ^a,c   Tisi, Dominic ^a,d   O'Reilly, Marc ^a,c   Seavers, Lisa C A ^a,e   Davis, Deborah J ^a,e   Curry, Jayne ^a,e   Anthony, Eachel ^a,e   Padova, Alessandro ^a,f,g   Murray, Christopher W ^a,f   Carr, Robin A E ^a,b   Jhoti, Harren ^a,c  

^a ASTEX PHARMACEUTICALS   (United Kingdom)

^b Medicinal Chemistry Group   (United Kingdom)

^c Protein Structure Group

^d Protein Technology Group   (Germany)

^e Biology Group

^f Compl Chem and Informatics Group ^*

^g UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 (4 PYRIDYL)ETHYL)INDOLE; 1 (5 TERT BUTYL 2H PYRAZOL 3 YL) 3 [4 CHLORO 3 (PYRIDIN 3 YLOXYMETHYL)PHENYL]UREA; 2 [4 (2 (3 INDOLYL)ETHYL) 2 PYRIMIDINYLAMINO] 2 METHYL 1 PROPANOL; 2 [5 (2,6 DICHLOROBENZYLOXY) 2 PYRIDINYLAMINO] 2 METHYL 1 PROPANOL; 2 [5 (2,6 DICHLOROBENZYLOXY) 2 PYRIDINYLAMINO]ETHANOL; 2 AMINO 3 (1 NAPHTHYLMETHYLOXY)PYRIDINE; 2 AMINO 3 (2,6 DICHLOROBENZYLOXY)PYRIDINE; 2 AMINO 3 BENZYLOXYPYRIDINE; 3 (2 (4 PYRIDYL)ETHYL)INDOLE; 3 [2 (2 CHLORO 4 PYRIMIDINYL)ETHYL]INDOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 6 AMINO 1 (2 (4 PYRIDYL)ETHYL)INDOLE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; N(5 INDOLYL) 3 FLUORO 5 (4 MORPHOLINO)BENZAMIDE; N[1 (2 (4 PYRIDYL)ETHYL) 5 INDOLYL] 3 FLUORO 5 (4 MORPHOLINO)BENZAMIDE; N[1 (2 (4 PYRIDYL)ETHYL) 6 INDOLYL] 3 FLUORO 5 (4 MORPHOLINO)BENZAMIDE; N[4 CHLORO 3 (3 PYRIDINYLOXYMETHYL)PHENYL] 3 FLUORO 5 (4 MORPHOLINO)BENZAMIDE; N[4 CHLORO 3 (3 PYRIDINYLOXYMETHYL)PHENYL]BENZAMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AMINOPYRIDINE DERIVATIVE; ENZYME INHIBITOR; INDOLE DERIVATIVE; LIGAND;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; FACTUAL DATABASE; PROTEIN BINDING; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

AMINOPYRIDINES; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; DATABASES, FACTUAL; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; INDOLES; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 19944434344     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049575n     Document Type: Article

References (42)

1. Han, J.; Lee, J. D.; Bibbs, L.; Ulevitch, R. J. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994, 265, 808-811.
2. Raingeaud, J.; Gupta, S.; Rogers, J. S.; Dickens, M.; Han, J.; Ulevitch, R. J.; David, R. J. Characterization of the structure and function of a novel MAP kinase kinase (MKK6). J. Biol. Chem. 1996, 271, 2886-2891.
3. Raingeaud, J.; Whitmarsh, A. J.; Barrett, T.; Derijard, B.; Davis, R. J. MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol. Cell Biol. 1996, 16, 1247.
4. Foster, M. L.; Halley, F.; Souness, J. E. Potential of p38 inhibitors in the treatment of rheumatoid arthritis. Drug News Perspect. 2000, 13, 488-497.
5. Rutgeerts, P.; D'Haens, G.; Targan, S.; Vasiliauskas, E.; Hanauer, S. B.; Present, D. H.; Mayer, L.; Van Hogezand, R. A.; Braakman, T.; DeWoody, K. L.; Schaible, T. F.; Van Deventer, S. J. H. Efficacy and safety of retreatment with anti-tumour necrosis factor antibody (Infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999, 117, 761-769.
6. Badger, A. M.; Bradbeer, J. N.; Votta, B.; Lee, J. C.; Adams, J. L.; Griswold, D. E. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J. Pharm. Exp. Ther. 1996, 279, 1453-1461.
7. Feldmann, M.; Brennan, F. M.; Maini, R. N. Role of Cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 1996, 14, 397-440.
8. Lee, J. C.; Laydon, J. T.; McDonnell, P. C.; Gallagher, T. F.; Kumar, S.; Greed, D. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994, 372, 739-746.
9. Gallagher, T. F.; Fier-Thompson, S. M.; Gargipati, R. S.; Sorenson, M. E.; Smietana, J. M.; Lee, D. 2,4,5-Triarylimidazole inhibitors of IL-1 biosynthesis. Bioorg. Med. Chem. Lett. 1995, 5, 1171-1176.
10. Jarvis, B.; Faulds, D. Etanercept: a review of its use in rheumatoid arthritis. Drugs 1999, 57, 945-966.
11. Garrison, L.; McDonnell, N. D. Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann. Rheum. Dis. 1999, 58 (Suppl. 1), 65-169.
12. Carteron, N. L. Cytokines in rheumatoid arthritis: trials and tribulations. Mol. Med. Today 2000, 6, 315-323.
13. Hamilton, K.; St. Glair, E. W. Tumour necrosis factor-alpha blockade: a new era for effective management of rheumatoid arthritis. Exp. Opin. Ther. Pat. 2000, 1, 1041-1052.
14. Kumar, S.; Boehm, J.; Lee, J. C. p38 MAP kinases: key signaling molecules as therapeutic targets for inflammatory diseases. Nature Rev. Drug Disc. 2003, 2, 717-726.
15. Chakravarty, S.; Dugar, S. Inhibitors of p38 alpha MAP kinase. Annu. Reports Med. Chem. 2002, 37, 177-186.
16. Cirillo, P. F.; Pargellis, C.; Regan, J. The nondiaryl heterocycle classes of p38 MAP kinase inhibitors. Curr. Topics Med. Chem. 2002, 2, 1021-1035.
17. Jackson, P. F.; Bullington, J. L. Pyridinylimidazole based p38 MAP kinase inhibitors. Curr. Topics Med. Chem. 2002, 2, 1011-1020.
18. Hartshorn, M. J.; Murray, C. W.; Cleasby, A.; Frederickson, M.; Tickle, I. J.; Jhoti, H. Fragment-based Lead Discovery Using X-ray Crystallography. J. Med. Chem. 2005, 48, 403-413.
19. Oprea, T. I. Current trends in lead discovery: are we looking for the appropriate properties? J. Comput.-Aided Mol. Des. 2002, 6, 325-334.
20. Blundell, T. L.; Jhoti, H.; Abell, C. High-throughput crystallography for lead discovery in drug design. Nat. Rev. Drug Discovery 2002, 1, 45-54.
21. Carr, R.; Jhoti, H. Structure-based screening of low-affinity compounds. Drug Discovery Today 2002, 7, 522-527.
22. Wang, Z.; Canagarajah, B. J.; Boehin, J. C.; Kassisa, S.; Cobb, M. H.; Young, P. R.; Abdel-Meguid, S.; Adams, J. L.; Goldsmith, E. J. Structural Basis of inhibitor selectivity in MAP kinases. Structure 1998, 6 1117-1128.
23. Bristol, J. A.; Gross, I.; Lovey, R. G. An improved synthesis of 2-Amino-3-alkoxypyridines by a phase-transfer catalysed ether synthesis. Synthesis 1981, 971-973.
24. Thompson, A. M.; Showalter, H. D.; Denny, William A. Synthesis of 7-substituted 3-aryl-1,6-naphthyridin-2-amines and 7-substituted 3-aryl-1,6-naphthyridin-2(1H)-ones via diazotization of 3-aryl-1,6- naphthyridine-2,7-diamines. J. Chem. Soc., Perkin Trans, 1 2000, 12, 1843-1852.
25. Gill, A. New lead generation strategies for protein kinase inhibitors -fragment based screening approaches. Mini-Rev. Med. Chem. 2004, 4, 301-311.
26. Pierce, A. C.; Sandretto, K. L.; Bemis, G. W. Kinase inhibitors and the case for CH⋯O hydrogen bonds in protein-ligand binding. Proteins 2002, 49, 567-576.
27. Lisnock, J.; Tebben, A.; Frantz, B.; O'Neill, E. A.; Croft, G.; O'Keefe, S. J.; Li, B.; Hacker, C.; de Laszlo, S.; Smith, A.; Libby, B.; Liverton, N.; Hermes, J.; LoGrasso, P. Molecular basis for p38 protein kinase inhibitor specificity. Biochemistry 1998, 37, 16573-16581.
28. Dumas, J.; Hatoum-Mokdad, H.; Sibley, R. N.; Smith, R. A.; Scott, W. J.; Khire, U.; Lee, W.; Wood, J.; Wolanin, D.; Cooley, J.; Bankston, D.; Redman, A. M.; Schoenleber, R.; Caringal, Y.; Gunn, D.; Romero, R.; Osterhout, M.; Paulsen, H.; Housley, T. J.; Wilhelm, S. M.; Pirro, J.; Chien, D.; Ranges, G. E.; Shrikhande, A.; Muzsi, A.; Bortolon, E.; Wakefield, J.; Gianpaolo Ostravage, C.; Bhargava, A.; Chau, T. Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor. Bioorg., Med. Chem. Lett. 2002, 12, 1559-1562.
29. Regan, J.; Capolino, A.; Cirillo, P. F.; Gilmore, T.; Graham, A. G.; Hickey, E.; Kroe, R. R.; Madwed, J.; Moriak, M.; Nelson, R.; Pargellis, C. A.; Swinamer, A.; Torcellini, C.; Tsang, M.; Moss, N. Structure-activity relationships of the p38a MAP kinase inhibitor 1-(5-Zert-Butyl-2-p-tolyl-2H- pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]urea (BIRB 796). J. Med. Chem. 2003,46, 4676-4686.
30. (b) Regan, J.; Breitfelder, S.; Cirillo, P.; Gilmore, T.; Graham, A. G.; Hickey, E.; Haus, B.; Madwed, J.; Moriak, M.; Moss, N.; Pargellis, C. A.; Pav, S.; Proto, A.; Swinamer, A.; Tong, L.; Torcellini, C. Pyrazole Urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. J. Med. Chem. 2002, 45, 2994-3008.
31. (c) Pargellis, C.; Tong, L.; Churchill, L.; Cirillo, P. F.; Gilmore, T.; Graham, A. G.; Grob, P. M.; Hickey, E. R.; Moss, N.; Pav, S.; Regan, J. Inhibition of p38 MAP Kinase by Utilizing a Novel Allosteric Binding Site. Nat. Struct. Biol. 2002, 9, 268-272.
32. Gray, A. P.; Archer, W. L. The Pyridylethylation of Indole and Related Reactions. J. Am. Chem. Soc. 1957, 79, 3554-3559.
33. Trejo, A.; Arzeno, H.; Browner, M.; Chanda, S.; Cheng, S.; Comer, D. D.; Dalrymple, S. A.; Dunten, P.; Lafargue, J.; Lovejoy, B.; Friere-Moar, J.; Lim, J.; Mcintosh, J.; Miller, J.; Papp, E.; Reuter, D.; Roberts, R.; Sanpablo, F.; Saunders: J.; Song, K.; Villasenor, A.; Warren, S. D.; Welch, M.; Weller, P.; Whiteley, P. E.; Zeng, L.; Goldstein, D. M. Design and Synthesis of 4-Azaindoles as Inhibitors of p38 MAP Kinase. J. Med. Chem. 2003, 46, 4702-4713.
34. Liverton, N. J.; Butcher, J. W.; Claiborne, C. F.; Claremon, D. A.; Libby, B. E.; Nguyen, K. T.; Pitzenberger, S. M.; Selnick, H. G.; Smith, G. R.; Tebben, A.; Vacca, J. P.; Varga, S. L.; Agarwal, L.; Dancheck, K.; Forsyth, A. J.; Fletcher, D. S.; Frantz, B.; Hanlon, W. A.; Harper, C. F.; Hofsess, S. J.; Kostura, M.; Lin, J.; Luell, S.; O'Neill, E. A.; Orevillo, C. J.; Pang, M.; Parsons, J.; Rolande, A.; Sahly, Y.; Visco, D. M.; O'Keefe, S. J. Design and Synthesis of Potent, Selective and Orally Bioavailable Tetrasubstituted Imidazole Inhibitors of p38 Mitogen-Activated Protein Kinase. J. Med. Chem. 1999, 42, 2180-2190.
35. Refined crystallographic coordinates for the structures of p38α complexed with 1, 2, 5, 9, 10, 16, 22, 23 and 24 have been deposited with the Protein Data Bank (www.rscb.org) with entry codes 1w7h, 1w84, 1wbw, 1w83, 1wbn, 1w82, 1wbv, 1wbs, 1wbt. respectively. PDB code for SB203580 is 1a9u.
36. Wang Z.; Harking P. C.; Ulevitch R. J.; Han J.; Cobb M. H.; Goldsmith E. J. The structure of mitogen-activated protein kinase p38 at 2.1 Å resolution. Proc Natl Acad Sci U.S.A. 1997, 6, 2327-2332.
37. Pflugrath, J. W. The finer things in X-ray diffraction data collection. Acta Crystallograph. D. Biol. Crystallogr. 1999, Oct; 55 (Pt 10), 1718-25.
38. Leslie, A.; Powell, H. Collaborative Computational Project, Number 4. The CCP4 Suite: Programs for Protein Crystallography. Acta Crystallogr. 1994 D50, 760-763.
39. Brunger, A. T. Free R value: A novel statistical quantity for assessing the accuracy of crystal structures. Nature 1992, 355, 472-475.
40. Murshudov, G. N., Vagin, A. A and Dodson, E. J. Refinement of Macromolecular Structures by the Maximum-Likelihood method. Acta Crystallogr. D. 2003, D53, 240-255.
41. Hartshorn, M. J. A visualization aid for structure based drug design. J Comput.-Aided Mol. Des. 2002, 16, 871-881.
42. QUANTA96 X-ray structure analysis, Users Reference; Molecular Simulations Inc: San Diego, CA, 1996.